Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features
Lumateperone 42 mg significantly improved depression symptoms and disease severity and was generally safe and well-tolerated in patients with MDD or bipolar depression with mixed features.
Authors
- Stephen M. Stahl (ORCID: https://orcid.org/0000-0002-6536-6973)
- Susan G Kozauer
- Suresh Durgam (ORCID: https://orcid.org/0000-0001-6629-0619)
- Changzheng Chen (ORCID: https://orcid.org/0000-0002-7281-552X)
- Hassan Lakkis
- Roger S. McIntyre (ORCID: https://orcid.org/0000-0003-4733-2523)
- Willie Earley
- Jason Huo (ORCID: https://orcid.org/0009-0004-2748-951X)
Institutions
- University of Toronto (CA)
- University of California San Diego (US)
- Intra Cellular Therapies (United States) (US)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1097/jcp.0000000000001964
- Citations
- 12
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 17.65